Literature DB >> 29057463

ALK-positive primary cutaneous anaplastic large cell lymphoma: a case report and review of the literature.

Shamir Geller1, Theresa N Canavan2, Melissa Pulitzer3, Alison J Moskowitz4, Patricia L Myskowski1.   

Abstract

Anaplastic large cell lymphoma (ALCL) limited to the skin is a distinct disease that is designated primary cutaneous ALCL (pcALCL). It has an indolent course with a significantly better prognosis compared to systemic ALCL (sALCL). Anaplastic lymphoma kinase (ALK) expression in lesions of cutaneous ALCL is classically considered to be a marker for skin involvement by sALCL. However, recent reports of patients with ALK-positive pcALCL challenge this concept and raise prognostic and therapeutic dilemmas. Herein, we report a case of ALK-positive pcALCL in a 45-year-old woman who was treated with local radiotherapy. We review previously reported cases in the literature to better characterize this rare variant. Overall, the rates of cutaneous recurrence, systemic dissemination, and disease-related mortality in ALK-positive pcALCL do not differ from those previously reported in pcALCL. ALK-positive pcALCL is diagnosed at younger age and has a better disease course in children compared to adults with lower incidences of skin recurrence and progression to systemic disease. We conclude that ALK-positivity in cutaneous ALCL does not necessarily imply systemic disease. ALK-positive pcALCL has an excellent prognosis and should be treated by excision and/or radiotherapy. However, patients must remain under close long-term follow-up as recurrence and progression to systemic disease may occur.
© 2017 The International Society of Dermatology.

Entities:  

Mesh:

Year:  2017        PMID: 29057463      PMCID: PMC5893427          DOI: 10.1111/ijd.13804

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  22 in total

1.  A case of anaplastic large cell lymphoma, ALK positive, primary presented in the skin and relapsed with systemic involvement and leukocytosis after years of follow-up period.

Authors:  Masataka Hosoi; Motoshi Ichikawa; Yoichi Imai; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2010-10-26       Impact factor: 2.490

Review 2.  ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study.

Authors:  Ilske Oschlies; Jasmin Lisfeld; Laurence Lamant; Atsuko Nakazawa; Emanuele S G d'Amore; Ulrika Hansson; Konnie Hebeda; Ingrid Simonitsch-Klupp; Jadwiga Maldyk; Leonhard Müllauer; Marianne Tinguely; Markus Stücker; Marie-Cecile Ledeley; Reiner Siebert; Alfred Reiter; Laurence Brugières; Wolfram Klapper; Wilhelm Woessmann
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

3.  Anaplastic lymphoma kinase expression in a recurrent primary cutaneous anaplastic large cell lymphoma with eventual systemic involvement.

Authors:  Derek V Chan; Pamela Summers; Marie Tuttle; Kevin D Cooper; Brenda Cooper; Henry Koon; Kord Honda
Journal:  J Am Acad Dermatol       Date:  2011-09       Impact factor: 11.527

4.  Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma.

Authors:  Heike Richly; Tae Min Kim; Martin Schuler; Dong-Wan Kim; Simon J Harrison; Alice T Shaw; Anthony L Boral; Alejandro Yovine; Benjamin Solomon
Journal:  Blood       Date:  2015-09-03       Impact factor: 22.113

5.  Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 cases.

Authors:  A Fauconneau; A Pham-Ledard; D Cappellen; E Frison; M Prochazkova-Carlotti; M Parrens; S Dalle; P Joly; R Viraben; F Franck; S Ingen-Housz-Oro; D Giacchero; M-L Jullié; B Vergier; J-P Merlio; M Beylot-Barry
Journal:  Br J Dermatol       Date:  2015-05-16       Impact factor: 9.302

6.  CD30+ lymphoproliferative disorder: primary cutaneous anaplastic large cell lymphoma followed by lymphomatoid papulosis.

Authors:  M Aoki; Y Niimi; S Takezaki; A Azuma; M Seike; S Kawana
Journal:  Br J Dermatol       Date:  2001-07       Impact factor: 9.302

Review 7.  Pediatric case of anaplastic lymphoma kinase-positive anaplastic large cell lymphoma forming a solitary skin tumor on the forearm.

Authors:  Michio Tokuyama; Yuta Kurashige; Tami Ota; Yasuaki Manabe; Hanako Yamaoka; Norihiro Ikoma; Akiko Fukumura; Michie Miyashita; Keisuke Otsubo; Tsuyoshi Morimoto; Hiroyuki Mochizuki; Natsuko Nakano; Naoya Nakamura; Akira Ozawa; Tomotaka Mabuchi
Journal:  J Dermatol       Date:  2016-11-18       Impact factor: 4.005

Review 8.  EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.

Authors:  Werner Kempf; Katrin Pfaltz; Maarten H Vermeer; Antonio Cozzio; Pablo L Ortiz-Romero; Martine Bagot; Elise Olsen; Youn H Kim; Reinhard Dummer; Nicola Pimpinelli; Sean Whittaker; Emmilia Hodak; Lorenzo Cerroni; Emilio Berti; Steve Horwitz; H Miles Prince; Joan Guitart; Teresa Estrach; José A Sanches; Madeleine Duvic; Annamari Ranki; Brigitte Dreno; Sonja Ostheeren-Michaelis; Robert Knobler; Gary Wood; Rein Willemze
Journal:  Blood       Date:  2011-08-12       Impact factor: 22.113

9.  ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.

Authors:  Kerry J Savage; Nancy Lee Harris; Julie M Vose; Fred Ullrich; Elaine S Jaffe; Joseph M Connors; Lisa Rimsza; Stefano A Pileri; Mukesh Chhanabhai; Randy D Gascoyne; James O Armitage; Dennis D Weisenburger
Journal:  Blood       Date:  2008-04-02       Impact factor: 22.113

10.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

Authors:  S W Morris; M N Kirstein; M B Valentine; K G Dittmer; D N Shapiro; D L Saltman; A T Look
Journal:  Science       Date:  1994-03-04       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.